Inari Medical : April 2024 Inari Medical Investor Presentation

Inari Medical

Investor Update

April 2024

Gema

FlowTriever Patient

This presentation and certain statements and information provided during this presentation may contain forward-looking statements. All statements other than statements of historical fact could be deemed forward-looking, including statements regarding our future results of operations and financial position, total procedures, total addressable market, research and development costs, and capital requirements; our business model and strategic plans for our products, technologies and business, including our implementation thereof; competitive companies and technologies and our industry; our ability to commercialize, manage and grow our business by expanding our sales and marketing organization and increasing our sales to existing and new customers; third-party payor reimbursement and coverage decisions; commercial success and market acceptance of our products; our ability to accurately forecast customer demand for our products and manage our inventory; our ability to establish and maintain intellectual property protection for our products or avoid claims of infringement; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States; the timing or likelihood of regulatory filings and approvals; acquisitions and investment initiatives, including the integration of LimFlow into our operations; our expectations regarding changes to patient standards of care; our ability to hire and retain key personnel; and our expectations about market trends. Without limiting the foregoing, the words "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words.

Forward-looking statements are based on and reflect management's current expectations, assumptions, estimates and projections that may or may not prove to be correct. These forward-looking statements are subject to a number of known and unknown risks, uncertainties, assumptions and other factors, many of which are beyond our control. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. Factors that could cause actual results to differ materially from those contemplated in this presentation can be found in the Risk Factors section of our public filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, available in the Investor Relations section of our website at https://ir.inarimedical.com/or at www.sec.gov.Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements in this presentation are made only as of the date hereof. Except to the extent required by law, we undertake no obligation to update or review any estimate, projection, or forward- looking statement. Actual results may differ from those set forth in this presentation due to the risks and uncertainties inherent in our business.

This presentation is not an offer to sell securities of Inari Medical and it is not soliciting offers to buy securities of Inari Medical nor will there be any sales of securities of Inari Medical in any state or jurisdiction where the offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Introduction

We've made improving lives our responsibility. And that drives our passion and success

Strategic objectives supporting continued strong growth and execution

Scale the adoption of highly	Continue to leverage our
differentiated, purpose-built	powerful commercial engine,
toolkits across large &	with the largest VTE focused sales
underpenetrated markets	force in the industry

Lead the way with high-quality, market-impactingclinical data: ~3,800 patients across 6 studies*

Deliver a premium financial profile: strong, durable growth, best-in-class gross margins, and increasing operating leverage

*6 leading clinical studies: FLARE, FLAME, CLOUT, PEERLESS RCT, PEERLESS II RCT, DEFIANCE RCT

Venous Thromboembolism (VTE)

~$2.8B Pulmonary Embolism

~$3.0B	Deep Vein
Thrombosis

~$10B U.S. TAM across 6 disease states

Emerging Therapies

~$1.0B	Chronic Venous
Disease

• ~$10B Prevalence TAM

Dialysis Access

~$1.0B Management

+ small venous thrombus

~$0.6B	Acute Limb
Ischemia

Chronic Limb

~$1.5B Threatening

Ischemia

Three growth pillars supported by global commercial playbook

Venous Thromboembolism (VTE)

Emerging Therapies

International

Driving our	• Pulmonary Embolism (PE)
solutions towards
standard of care	• Deep Vein Thrombosis (DVT)
in VTE
Building	• Chronic Venous Disease (CVD)
momentum with	• Dialysis Access Management (DAM)
new products in	• Acute Limb Ischemia (ALI)
new markets	• Chronic Limb Threatening Ischemia (CLTI)
Expanding our	• EMEA: ~20 active countries
footprint	• APAC & LAC: ~12 active countries
internationally	• China & Japan commercial in 2024

Commercial Playbook

§	Developing purpose-built solutions	§	Standardizing patient pathways
§	Executing guideline changing clinical trials	§	Expanding our commercial footprint

Venous Thromboembolism (VTE)

Transforming the lives of patients suffering from DVT

DEEP VEIN THROMBOSIS (DVT)

• A/C alone leaves clot behind in up to half of patients1
• Lytics don't address chronic clot, and come with bleeding risk
• Up to 50% develop Post- Thrombotic Syndrome (PTS)2

DVT TAM

Intervention Conservative Mgmt

430,000

US Patients

$3.0B

TAM

1. Young et al., Post-treatment residual thrombus increases the risk of recurrent deep vein thrombosis and mortality. J Thromb Haemost 2006; 4: 1919-24.
2. Kahn, Susan R. Hematology Am Soc Hematol Educ Program. 2016 Dec 2; 2016(1): 413-418

The ClotTriever® System: A complete solution for DVT and peripheral venous thrombus

Access	Acute to Chronic Clot	Comprehensive DVT
Removal

ClotTriever & ClotTriever BOLD	ProTrieve Sheath
Catheters

ClotTriever Sheath

13F and 16F

Fourth Generation Triever	ClotTriever XL Catheter
Catheters
(for peripheral thrombus)

INDICATIONS FOR USE: The ClotTriever thrombectomy system is indicated for: (1) The non-surgical removal of thrombi and emboli from blood vessels. (2) Injection, infusion, and/ or aspiration of contrast media and other fluids into or from a blood vessel. The ClotTriever thrombectomy system is intended for use in the peripheral vasculature including deep vein thrombosis (DVT). The Protrieve Sheath is indicated for use as a conduit for the insertion of endovascular devices into the vasculature while minimizing blood loss associated with such insertions. The FlowTriever retrieval/aspiration system is indicated for (1) the non-surgical removal of emboli and thrombi from blood vessels (2) injection, infusion and/or aspiration of contrast media and other fluids into or from a blood vessel. The FlowTriever retrieval/aspiration system is intended for use in the peripheral vasculature and for the treatment of pulmonary embolism. Triever catheters are intended for use in peripheral vasculature and for the treatment of pulmonary embolism. Triever catheters are also intended for use in treating clot in transit in the right atrium, but not in conjunction with FlowTriever Catheter. The FlowTriever2® catheter is indicated for the non-surgical removal of emboli and thrombi from peripheral blood vessels. Injection, infusion, and/or aspiration of contrast media and other fluids into or from a blood vessel. The

FlowTriever2 catheter is intended for use in the peripheral vasculature. Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. All trademarks are property of their respective owners.